Healthcare Industry News: Radixact System
News Release - September 19, 2019
Accuray Educates Radiation Oncology Practices on the Potential Impact of the Proposed Alternative Payment Model (RO-APM)SUNNYVALE, Calif., Sept. 19, 2019 -- (Healthcare Sales & Marketing Network) -- Accuray Incorporated (NASDAQ: ARAY) today published an informational guide designed to help radiation oncology practices understand the complexities of the much-anticipated proposed Medicare & Medicaid reimbursement changes. The new guide — available at www.accuray.com/apm/ — serves as an informational tool for healthcare providers who find themselves balancing their desire to invest in improved patient treatment technologies with the disruptiveness of a new billing model. Titled, "Thriving Under the Radiation Oncology Alternative Payment Model: A Definitive Guide to a New Reality," the guide aims to help radiation oncology professionals understand the changes outlined in the Radiation Oncology – Alternative Payment Model (RO-APM).
The July 2019 announcement of the RO-APM outlined a progressive course toward value-based care, shifting reimbursement to prospective, episode-based payments and providing equal base-rate compensation at the tumor-site-specific level — regardless of technique or modality, number of fractions delivered or setting of care. Among the immediately evident impacts, the episodic payment model aligns patient, provider and payer interests with a shift to delivering hypofractionated radiotherapy wherever clinically appropriate — which should firmly establish hypofractionation as an essential treatment modality.
"Growing evidence demonstrates hypofractionation as a proven treatment modality that delivers clinical outcomes as good as conventional fractionation while dramatically reducing the number of treatments — and dramatically lowering the total cost of care," said Levine. "As both the pioneer and the continued innovation leader in hypofractionation, Accuray provides an unmatched set of tools developed specifically to give radiation oncologists the confidence they need to deliver safe, efficient and effective hypofractionated treatments to their patients."
Accuray innovations in hypofractionated radiotherapy include two of the most accurate and precise treatment delivery systems in the industry — the CyberKnife® and Radixact® Systems — capable of delivering hypofractionated SBRT treatments to targets anywhere in the body. Sophisticated dose-sculpting capabilities enable clinicians to create treatment plans with significantly smaller margins and sharper dose gradients. Accuray Synchrony® technology provides the industry's only fully integrated motion synchronization solution, automatically and precisely synchronizing treatment delivery with real-time target motion.
"Accuray technologies are designed to provide clinicians with the resources they need to achieve both their clinical efficacy and ROI goals. With the proposed new payment model, we believe that hypofractionated treatments will provide an increasingly important means of accomplishing these goals," said Birgit Fleurent, Chief Marketing Officer of Accuray. "The CyberKnife and Radixact Systems offer a unique combination of capabilities such as dose-sculpting, multi-angle delivery and motion synchronization, that make it easier to successfully deliver hypofractionated treatments — a process necessitating an extremely high degree of precision and accuracy. Clinicians can feel confident they will be able to optimize patient care during all stages of the treatment journey."
Important Safety Information
For Important Safety Information please refer to https://www.accuray.com/safety-statement.
Accuray Incorporated (Nasdaq: ARAY) develops, manufactures and sells radiotherapy systems that are intended to make cancer treatments shorter, safer, personalized and more effective, ultimately enabling patients to live longer, better lives. Our radiation treatment delivery systems in combination with fully-integrated software solutions set the industry standard for precision and cover the full range of radiation therapy and radiosurgery procedures. For more information, please visit www.accuray.com or follow us on Facebook, LinkedIn, Twitter and YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to the expected impact of the Radiation Oncology – Alternative Payment Model, including its impact on clinical best practices, expectations regarding the role and importance of hypofractionated treatments under the new payment model, clinical applications, clinical experiences and results, patient experiences, and patient outcomes. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the company's ability to achieve widespread market acceptance of its products; the company's ability to develop new products or improve existing products to meet customers' needs; the company's ability to anticipate or keep pace with changes in the marketplace and the direction of technological innovation and customer demands and such other risks identified under the heading "Risk Factors" in the company's annual report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 23, 2019, and as updated periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsTrial Data Indicates Targeted, Short Course Radiation Therapy Preserves Urinary Continence and Sexual Function Better Than Surgery in Men With Prostate Cancer
Oscar Lambret Center in France Installs Second Accuray Radixact(R) System, the Hospital's Fifth Accuray Radiation Therapy Delivery System
New Reimbursement Approved by the Japanese Ministry of Health, Labor and Welfare for the Accuray CyberKnife(R) System to Treat Trigeminal Neuralgia, a Condition Often Causing Severe Facial Pain